---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-061851"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:15:41.306382+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance

## Summary
- Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.
- Net loss narrowed to $29.8M from $47.5M; adjusted EBITDA loss $12.7M from $28.2M.
- Raises FY 2025 MRD revenue guidance to $180-190M (from $175-185M); lowers cash burn target to $50-60M.
- Expanded Medicare coverage for clonoSEQ in mantle cell lymphoma recurrence monitoring.
- Cash, equivalents, and marketable securities $232.8M at March 31, 2025.

## SEC filing metadata
- accession: 0000950170-25-061851
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017025061851/0000950170-25-061851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017025061851/adpt-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-061851
- JSON: https://secwatch.observer/filing/0000950170-25-061851.json
- Plain text: https://secwatch.observer/filing/0000950170-25-061851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.